Acelot, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, developing first-in-class small-molecule therapies for neurodegenerative diseases with high unmet need. Its lead candidate, ACE-2223, is designed to target misfolded and aggregated TDP-43 and restore the protein's healthy form and function, addressing pathology central to amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Acelot's discovery work is powered by Resolute, an internal integrated drug-discovery platform combining AI-driven computational chemistry with structural and biological insight to drug historically intractable protein targets. Acelot publishes no public API, developer portal, SDK or machine-readable specification; its four public GitHub repositories are forks of third-party cheminformatics tooling.
Acelot is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Drug Discovery, and Life Sciences.
Acelot’s developer surface includes engineering blog and 8 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/acelot-inc: open an issue to ask a question, or submit a pull request to add artifacts.
Submit an artifact on GitHub — free →Manage your own listing — the Influence plan, $499/mo →
aid: acelot-inc
name: Acelot
description: Acelot, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California,
developing first-in-class small-molecule therapies for neurodegenerative diseases with high unmet need. Its lead candidate,
ACE-2223, is designed to target misfolded and aggregated TDP-43 and restore the protein's healthy form and function, addressing
pathology central to amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Acelot's discovery
work is powered by Resolute, an internal integrated drug-discovery platform combining AI-driven computational chemistry
with structural and biological insight to drug historically intractable protein targets. Acelot publishes no public API,
developer portal, SDK or machine-readable specification; its four public GitHub repositories are forks of third-party cheminformatics
tooling.
image: https://static1.squarespace.com/static/6721bd430e24a6572ea4152a/t/6732691e70799e3f6a4e8b71/1731356958733/Acelot-Website-LogoKnockout-111124-v01.png?format=1500w
url: https://raw.githubusercontent.com/api-evangelist/acelot-inc/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-09-06'
modified: '2026-09-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Life Sciences
- Neurodegenerative Disease
- Artificial Intelligence
- Computational Chemistry
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: Website
url: https://www.acelot.com/
- type: Blog
url: https://www.acelot.com/news
- type: BlogRSS
url: https://www.acelot.com/news?format=rss
- type: GitHubOrganization
url: https://github.com/acelot-inc
- type: LinkedIn
url: https://www.linkedin.com/company/acelot-inc./
- type: x-Publications
url: https://www.acelot.com/publications
- type: x-Team
url: https://www.acelot.com/our-team
- type: DomainSecurity
url: security/acelot-inc-domain-security.yml
- type: LLMsTxt
url: llms/acelot-inc-llms.txt
x-enrichment:
date: '2026-09-06'
status: minimal
artifacts_added: 3
pass: local-v3
x-coverage:
state: none
reason: no-developer-program
detail: Acelot is a clinical-stage biopharmaceutical company whose product is a small-molecule therapeutic (ACE-2223), and
its Resolute AI drug-discovery platform is described by the company as employed in-house only — acelot.com is a five-page
Squarespace marketing site with no developer, docs or API section, and every contract-discovery path returned 404 on both
acelot.com and www.acelot.com.
evidence:
- url: https://www.acelot.com/pipeline-and-platform
status: 200
- url: https://www.acelot.com/openapi.json
status: 404
- url: https://www.acelot.com/swagger.json
status: 404
- url: https://www.acelot.com/api-docs
status: 404
- url: https://www.acelot.com/graphql
status: 404
- url: https://www.acelot.com/mcp
status: 404
- url: https://www.acelot.com/llms.txt
status: 404
- url: https://www.acelot.com/.well-known/agent-card.json
status: 404
- url: https://www.acelot.com/.well-known/api-catalog
status: 404
- url: https://github.com/acelot-inc
status: 200
checked: '2026-09-06'
x-legal-name: Acelot, Inc.
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.